SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

Rhea-AI Summary

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management will host a fireside chat on August 14, 2024, at 3:30 p.m. Eastern Time.

Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's growth strategies and market position in the medical device industry.

SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.

Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,900 physicians in performing a total of over 100,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

iFuse Bedrock Granite, iFuse-TORQ, SI-BONE and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.

Investor Contact: Saqib Iqbal investors@si-bone.com

FAQ

When is SI-BONE (SIBN) presenting at the Canaccord Genuity Growth Conference in 2024?

SI-BONE (SIBN) is presenting at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024, at 3:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

How can investors listen to SI-BONE's (SIBN) presentation at the Canaccord Genuity conference?

Investors can listen to SI-BONE's (SIBN) presentation by registering through a link provided in the press release. The webcast will also be available live on the 'Investors' section of SI-BONE's website.

How long will the webcast of SI-BONE's (SIBN) presentation be available for replay?

The webcast of SI-BONE's (SIBN) presentation will be archived and available for replay for at least 90 days after the event.

What is the focus of SI-BONE (SIBN) as a medical device company?

SI-BONE (SIBN) is a medical device company dedicated to solving sacropelvic disorders.